LAG-3 and PD-1+LAG-3 inhibition promote anti-tumor immune responses in human autologous melanoma/T cell co-cultures

References

• Anderson KG, Stromnes IM, Greenberg PD. 2017. Obstacles posed by the tumor microenvironment to T cell activity: a case for synergistic therapies. Cancer Cell. 31:311–10. doi:10.1016/j.ccell.2017.02.008.
   PubMed Web of Science ®Google Scholar
• Callahan MK, Postow MA, Wolchok JD. 2016. Targeting T cell co-receptors for cancer therapy. Immunity. 44:1069–1078. doi:10.1016/j.immuni.2016.04.023.
   PubMed Web of Science ®Google Scholar
• Jenkins RW, Barbie DA, Flaherty KT. 2018. Mechanisms of resistance to immune checkpoint inhibitors. Br J Cancer. 118:9–16. doi:10.1038/bjc.2017.434.
   PubMed Web of Science ®Google Scholar
• Speiser DE, Ho PC, Verdeil G. 2016. Regulatory circuits of T cell function in cancer. Nat Rev Immunol. 16:599–611. doi:10.1038/nri.2016.80.
   PubMed Web of Science ®Google Scholar
• Wherry EJ, Ha SJ, Kaech SM, Haining WN, Sarkar S, Kalia V, Subramaniam S, Blattman JN, Barber DL, Ahmed R. 2007. Molecular signature of CD8+ T cell exhaustion during chronic viral infection. Immunity. 27:670–684. doi:10.1016/j.immuni.2007.09.006.
   PubMed Web of Science ®Google Scholar
• Fuertes Marraco SA, Neubert NJ, Verdeil G, Speiser DE. 2015. Inhibitory receptors beyond T cell exhaustion. Front Immunol. 6:310. doi:10.3389/fimmu.2015.00310.
   PubMed Web of Science ®Google Scholar
• Ribas A, Wolchok JD. 2018. Cancer immunotherapy using checkpoint blockade. Science. 359:1350–1355. doi:10.1126/science.aar4060.
   PubMed Web of Science ®Google Scholar
• Odorizzi PM, Pauken KE, Paley MA, Sharpe A, Wherry EJ. 2015. Genetic absence of PD-1 promotes accumulation of terminally differentiated exhausted CD8+ T cells. J Exp Med. 212:1125–1137. doi:10.1084/jem.20142237.
   PubMed Web of Science ®Google Scholar
• Mueller SN, Vanguri VK, Ha SJ, West EE, Keir ME, Glickman JN, Sharpe AH, Ahmed R. 2010. PD-L1 has distinct functions in hematopoietic and nonhematopoietic cells in regulating T cell responses during chronic infection in mice. J Clin Invest. 120:2508–2515. doi:10.1172/JCI40040.
   PubMed Web of Science ®Google Scholar
• Wei SC, Levine JH, Cogdill AP, Zhao Y, Anang NAS, Andrews MC, Sharma P, Wang J, Wargo JA, Pe’er D, et al. 2017. Distinct cellular mechanisms underlie anti-CTLA-4 and anti-PD-1 checkpoint blockade. Cell. 170:1120–1133 e1117. doi:10.1016/j.cell.2017.07.024.
   PubMed Web of Science ®Google Scholar
• Pardoll DM. 2012. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 12:252–264. doi:10.1038/nrc3239.
   PubMed Web of Science ®Google Scholar
• De Sousa Linhares A, Leitner J, Grabmeier-Pfistershammer K, Steinberger P. 2018. Not all immune checkpoints are created equal. Front Immunol. 9:1909. doi:10.3389/fimmu.2018.01909.
   PubMed Web of Science ®Google Scholar
• Walunas TL, Lenschow DJ, Bakker CY, Linsley PS, Freeman GJ, Green JM, Thompson CB, Bluestone JA. 1994. CTLA-4 can function as a negative regulator of T cell activation. Immunity. 1:405–413. doi:10.1016/1074-7613(94)90071-X.
   PubMed Web of Science ®Google Scholar
• Schadendorf D, Hodi FS, Robert C, Weber JS, Margolin K, Hamid O, Patt D, Chen TT, Berman DM, Wolchok JD. 2015. Pooled analysis of long-term survival data from phase II and phase III trials of ipilimumab in unresectable or metastatic melanoma. J Clin Oncol. 33:1889–1894. doi:10.1200/JCO.2014.56.2736.
   PubMed Web of Science ®Google Scholar
• Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, Powderly JD, Carvajal RD, Sosman JA, Atkins MB, et al. 2012. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 366:2443–2454. doi:10.1056/NEJMoa1200690.
   PubMed Web of Science ®Google Scholar
• Brahmer JR, Tykodi SS, Chow LQ, Hwu WJ, Topalian SL, Hwu P, Drake CG, Camacho LH, Kauh J, Odunsi K, et al. 2012. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med. 366:2455–2465. doi:10.1056/NEJMoa1200694.
   PubMed Web of Science ®Google Scholar
• Herbst RS, Soria JC, Kowanetz M, Fine GD, Hamid O, Gordon MS, Sosman JA, McDermott DF, Powderly JD, Gettinger SN, et al. 2014. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature. 515:563–567. doi:10.1038/nature14011.
   PubMed Web of Science ®Google Scholar
• Powles T, Eder JP, Fine GD, Braiteh FS, Loriot Y, Cruz C, Bellmunt J, Burris HA, Petrylak DP, Teng SL, et al. 2014. MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer. Nature. 515:558–562. doi:10.1038/nature13904.
   PubMed Web of Science ®Google Scholar
• Tumeh PC, Harview CL, Yearley JH, Shintaku IP, Taylor EJ, Robert L, Chmielowski B, Spasic M, Henry G, Ciobanu V, et al. 2014. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature. 515:568–571. doi:10.1038/nature13954.
   PubMed Web of Science ®Google Scholar
• Zappasodi R, Merghoub T, Wolchok JD. 2018. Emerging concepts for immune checkpoint blockade-based combination therapies. Cancer Cell. 33:581–598. doi:10.1016/j.ccell.2018.03.005.
   PubMed Web of Science ®Google Scholar
• Patel SA, Minn AJ. 2018. Combination cancer therapy with immune checkpoint blockade: mechanisms and strategies. Immunity. 48:417–433. doi:10.1016/j.immuni.2018.03.007.
   PubMed Web of Science ®Google Scholar
• Sakuishi K, Apetoh L, Sullivan JM, Blazar BR, Kuchroo VK, Anderson AC. 2010. Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity. J Exp Med. 207:2187–2194. doi:10.1084/jem.20100643.
   PubMed Web of Science ®Google Scholar
• Woo SR, Turnis ME, Goldberg MV, Bankoti J, Selby M, Nirschl CJ, Bettini ML, Gravano DM, Vogel P, Liu CL, et al. 2012. Immune inhibitory molecules LAG-3 and PD-1 synergistically regulate T-cell function to promote tumoral immune escape. Cancer Res. 72:917–927. doi:10.1158/0008-5472.CAN-11-1620.
   PubMed Web of Science ®Google Scholar
• Derre L, Rivals JP, Jandus C, Pastor S, Rimoldi D, Romero P, Michielin O, Olive D, Speiser DE. 2010. BTLA mediates inhibition of human tumor-specific CD8+ T cells that can be partially reversed by vaccination. J Clin Invest. 120:157–167. doi:10.1172/JCI40070.
   PubMed Web of Science ®Google Scholar
• Fourcade J, Sun Z, Pagliano O, Guillaume P, Luescher IF, Sander C, Kirkwood JM, Olive D, Kuchroo V, Zarour HM. 2012. CD8(+) T cells specific for tumor antigens can be rendered dysfunctional by the tumor microenvironment through upregulation of the inhibitory receptors BTLA and PD-1. Cancer Res. 72:887–896. doi:10.1158/0008-5472.CAN-11-2637.
   PubMed Web of Science ®Google Scholar
• Lasaro MO, Sazanovich M, Giles-Davis W, Mrass P, Bunte RM, Sewell DA, Hussain SF, Fu YX, Weninger W, Paterson Y, et al. 2011. Active immunotherapy combined with blockade of a coinhibitory pathway achieves regression of large tumor masses in cancer-prone mice. Mol Ther. 19:1727–1736. doi:10.1038/mt.2011.88.
   PubMed Web of Science ®Google Scholar
• Speiser DE, Wieckowski S, Gupta B, Iancu EM, Baumgaertner P, Baitsch L, Michielin O, Romero P, Rufer N. 2011. Single cell analysis reveals similar functional competence of dominant and nondominant CD8 T-cell clonotypes. Proc Natl Acad Sci USA. 108:15318–15323. doi:10.1073/pnas.1105419108.
   PubMed Web of Science ®Google Scholar
• Zippelius A, Batard P, Rubio-Godoy V, Bioley G, Lienard D, Lejeune F, Rimoldi D, Guillaume P, Meidenbauer N, Mackensen A, et al. 2004. Effector function of human tumor-specific CD8 T cells in melanoma lesions: a state of local functional tolerance. Cancer Res. 64:2865–2873. doi:10.1158/0008-5472.CAN-03-3066.
   PubMed Web of Science ®Google Scholar
• Tang J, Yu JX, Hubbard-Lucey VM, Neftelinov ST, Hodge JP, Lin Y. 2018. Trial watch: the clinical trial landscape for PD1/PDL1 immune checkpoint inhibitors. Nat Rev Drug Discov. 17:854–855. doi:10.1038/nrd.2018.210.
   PubMed Web of Science ®Google Scholar
• Matsuzaki J, Gnjatic S, Mhawech-Fauceglia P, Beck A, Miller A, Tsuji T, Eppolito C, Qian F, Lele S, Shrikant P, et al. 2010. Tumor-infiltrating NY-ESO-1-specific CD8+ T cells are negatively regulated by LAG-3 and PD-1 in human ovarian cancer. Proc Natl Acad Sci USA. 107:7875–7880. doi:10.1073/pnas.1003345107.
   PubMed Web of Science ®Google Scholar
• Baitsch L, Legat A, Barba L, Fuertes Marraco SA, Rivals JP, Baumgaertner P, Christiansen-Jucht C, Bouzourene H, Rimoldi D, Pircher H, et al. 2012. Extended co-expression of inhibitory receptors by human CD8 T-cells depending on differentiation, antigen-specificity and anatomical localization. PLoS One. 7:e30852. doi:10.1371/journal.pone.0030852.
   PubMed Web of Science ®Google Scholar
• Johnson DB, Estrada MV, Salgado R, Sanchez V, Doxie DB, Opalenik SR, Vilgelm AE, Feld E, Johnson AS, Greenplate AR, et al. 2016. Melanoma-specific MHC-II expression represents a tumour-autonomous phenotype and predicts response to anti-PD-1/PD-L1 therapy. Nat Commun. 7:10582. doi:10.1038/ncomms10582.
   PubMed Web of Science ®Google Scholar
• Demotte N, Wieers G, Van Der Smissen P, Moser M, Schmidt C, Thielemans K, Squifflet JL, Weynand B, Carrasco J, Lurquin C, et al. 2010. A galectin-3 ligand corrects the impaired function of human CD4 and CD8 tumor-infiltrating lymphocytes and favors tumor rejection in mice. Cancer Res. 70:7476–7488. doi:10.1158/0008-5472.CAN-10-0761.
   PubMed Web of Science ®Google Scholar
• Baitsch L, Baumgaertner P, Devevre E, Raghav SK, Legat A, Barba L, Wieckowski S, Bouzourene H, Deplancke B, Romero P, et al. 2011. Exhaustion of tumor-specific CD8(+) T cells in metastases from melanoma patients. J Clin Invest. 121:2350–2360. doi:10.1172/JCI46102.
   PubMed Web of Science ®Google Scholar
• Fourcade J, Sun Z, Benallaoua M, Guillaume P, Luescher IF, Sander C, Kirkwood JM, Kuchroo V, Zarour HM. 2010. Upregulation of Tim-3 and PD-1 expression is associated with tumor antigen-specific CD8+ T cell dysfunction in melanoma patients. J Exp Med. 207:2175–2186. doi:10.1084/jem.20100637.
   PubMed Web of Science ®Google Scholar
• Ngiow SF, von Scheidt B, Akiba H, Yagita H, Teng MW, Smyth MJ. 2011. Anti-TIM3 antibody promotes T cell IFN-gamma-mediated antitumor immunity and suppresses established tumors. Cancer Res. 71:3540–3551. doi:10.1158/0008-5472.CAN-11-0096.
   PubMed Web of Science ®Google Scholar
• Avery L, Filderman J, Szymczak-Workman AL, Kane LP. 2018. Tim-3 co-stimulation promotes short-lived effector T cells, restricts memory precursors, and is dispensable for T cell exhaustion. Proc Natl Acad Sci USA. 115:2455–2460. doi:10.1073/pnas.1712107115.
   PubMed Web of Science ®Google Scholar
• Huang YH, Zhu C, Kondo Y, Anderson AC, Gandhi A, Russell A, Dougan SK, Petersen BS, Melum E, Pertel T, et al. 2015. CEACAM1 regulates TIM-3-mediated tolerance and exhaustion. Nature. 517:386–390. doi:10.1038/nature13848.
   PubMed Web of Science ®Google Scholar
• Yan W, Liu X, Ma H, Zhang H, Song X, Gao L, Liang X, Ma C. 2015. Tim-3 fosters HCC development by enhancing TGF-beta-mediated alternative activation of macrophages. Gut. 64:1593–1604. doi:10.1136/gutjnl-2014-307671.
   PubMed Web of Science ®Google Scholar